Clinical trials - page 7

A prospective, multicenter, open-label, randomized international Phase III study evaluating treatment with lutetium (177Lu) vipivotide tetraxetan (AAA617) versus surveillance alone to delay the need for castration or disease recurrence in adult male patients with PSMA-positive oligometastatic prostate cancer.

CAMBRIA-2: A Phase III, Randomised, Open-label Study to Evaluate the Efficacy and Safety of Camizestrant (AZD9833), a Next Generation Oral Selective Estrogen Receptor Degrader (ngSERD), Compared with Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment in Patients with Estrogen Receptor-positive, HER2-negative Early Breast Cancer at Medium to High or High Risk of Recurrence, Who Have Completed Definitive Locoregional Therapy and Have No Evidence of Disease.

A Cohort to Quantify and to Predict Treatment Related Chronic Toxicities in Patients With Non-metastatic Breast Cancer

A Cohort to Quantify and to Predict Treatment Related Chronic Toxicities in Patients With Non-metastatic Breast Cancer.

Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery (CAPPA).

An open label, multi-center roll-over study to assess longterm;effect in pediatric patients treated with Tafinlar;(dabrafenib) and/or Mekinist (trametinib)

Evaluation of the quality of life induced by the anti-odor cinnamon dressing in patients with malodorous wounds: a multicenter randomized controlled trial.

Open-label, non-randomized, Phase 1b/2 trial investigating the;safety, tolerability, and antitumor activity of S095029 (anti-;NKG2A antibody) as a part of combination therapy in participants;with locally advanced and unresectable or metastatic MSIH/;dMMR gastroesophageal junction /gastric cancer

Open-label, non-controlled, multicenter, dose escalation, first-in-human phase I clinical trial to evaluate the safety, pharmacokinetics and preliminary antitumor activity of intravenous PEP-010, administered as single agent and in combination with paclitaxel in patients with recurrent and/or metastatic solid cancer.

Long-term cognitive and functional impact of proton-therapy or modern fractionated radiotherapy in cavernous sinus meningioma: An open-label randomized 1:1 phase III study